Plant Name: Melicope sarcococca
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| TDP1; CTDSP1; RECQL; BLM; HSD17B1; AKR1B1; HSD17B2; HSD17B10; HPGD; NOX4; ALOX15; USP2; APEX1; POLB; | |
| DUSP3; | |
| GAA; | |
| FLT4; EPHB4; PDGFRB; INSR; DAPK1; AKT1; PLK4; MET; FLT3; IGF1R; ERBB2; EGFR; TEK; NUAK1; AURKA; PLK1; KDR; GSK3B; SRC; MAP3K8; BRAF; AURKB; PTK2; CSNK2A1; | |
| CA2; CA12; CA9; CA13; CA14; CA5A; CA7; CA4; CA6; | |
| AR; | |
| ESRRA; | |
| ALOX5; TYR; XDH; | |
| KDM4E; | |
| BACE1; | |
| AHR; HIF1A; TP53; | |
| SLCO1B3; SLC22A6; SLCO1B1; | |
| ABCG2; ABCC1; | |
| HBB; LMNA; SMAD3; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
| Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
| Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
| Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.756E-13 | 4.828E-10 | CA12, CA13, CA2, CA4, CA5A, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.759E-12 | 2.453E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, HBB, NOX4 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.406E-10 | 3.977E-08 | ABCC1, CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, SLCO1B1, SLCO1B3, TEK |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.913E-10 | 5.272E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.983E-10 | 1.448E-07 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, HBB, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.611E-09 | 3.218E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, HBB, NOX4, SRC |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.126E-09 | 5.844E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 7.357E-09 | 1.252E-06 | EGFR, ERBB2, INSR, MET, NOX4, PDGFRB, PTK2, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.494E-08 | 2.324E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.602E-08 | 3.778E-06 | EGFR, ERBB2, INSR, KDR |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.645E-08 | 3.803E-06 | EGFR, IGF1R, INSR, KDR, PTK2, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 3.916E-08 | 5.397E-06 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 6.987E-08 | 9.276E-06 | ALOX15, BRAF, EGFR, FLT4, KDR, NOX4, PDGFRB, SRC, TEK |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.013E-07 | 1.289E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.018E-07 | 1.289E-05 | FLT3, PDGFRB, PTK2, SRC, TEK |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.243E-07 | 2.598E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 2.770E-07 | 3.158E-05 | FLT3, FLT4, KDR, PDGFRB |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 3.117E-07 | 3.481E-05 | AKT1, AURKA, BRAF, DUSP3, EGFR, GSK3B, HIF1A, PDGFRB, PLK1, PTK2, SMAD3, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 5.180E-07 | 5.422E-05 | AKT1, EGFR, HBB, INSR, SMAD3 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 5.328E-07 | 5.551E-05 | ALOX15, EGFR, ERBB2, PDGFRB, SMAD3, TP53 |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.115E-06 | 1.047E-04 | ALOX15, ALOX5, HPGD |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.193E-06 | 1.110E-04 | CYP1A1, PDGFRB, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 1.436E-06 | 1.304E-04 | AKR1B1, AKT1, APEX1, GSK3B, IGF1R, INSR, SRC, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.755E-06 | 1.529E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.946E-06 | 1.662E-04 | FLT3, FLT4, KDR |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 2.967E-06 | 2.324E-04 | AKT1, AR, DAPK1, HSPA1A, LMNA, SRC |
| BP | GO:0032502; developmental process | GO:0007568; aging | 3.138E-06 | 2.449E-04 | AKT1, APEX1, AURKB, CYP1A1, NOX4, PDGFRB, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 4.251E-06 | 3.170E-04 | AKR1B1, AKT1, EGFR, HSD17B2, KDR, PDGFRB, SLC22A6, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 4.644E-06 | 3.417E-04 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 5.451E-06 | 3.917E-04 | AKT1, AURKA, AURKB, BLM, CSNK2A1, NUAK1, TP53 |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 5.728E-06 | 4.089E-04 | FLT3, KDR, PDGFRB, PTK2, TEK |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 6.531E-06 | 4.602E-04 | AKT1, EGFR, ERBB2, FLT4, MET, TP53 |
| BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 6.690E-06 | 4.684E-04 | CYP1B1, EPHB4, FLT4, HIF1A, KDR, PDGFRB, PTK2, TEK |
| BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 6.942E-06 | 4.814E-04 | EPHB4, GAA, INSR, PTK2 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 6.942E-06 | 4.814E-04 | AHR, CSNK2A1, HIF1A, KDR |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 7.664E-06 | 5.298E-04 | BLM, GSK3B, HIF1A, NUAK1, TP53 |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 1.149E-05 | 7.698E-04 | AKR1B1, AKT1, EGFR, HPGD, PDGFRB |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.206E-05 | 8.032E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 1.256E-05 | 8.340E-04 | AKT1, CA2, PDGFRB, SRC |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.336E-05 | 8.814E-04 | AR, BLM, CA12, CA13, CA2, CA4, CA5A, CA6, CA7, CA9, ESRRA, SMAD3, TP53 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.488E-05 | 9.669E-04 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 1.570E-05 | 1.011E-03 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.570E-05 | 1.011E-03 | AKR1B1, AKT1, AR, EGFR, SRC |
| BP | Unclassified; | GO:0006461; protein complex assembly | 1.644E-05 | 1.056E-03 | AR, BLM, BRAF, GSK3B, HBB, HSD17B10, HSPA1A, IGF1R, INSR, PTK2, SLC22A6, SMAD3, SRC, TEK, TP53 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.985E-05 | 1.246E-03 | AR, EGFR, HSD17B1, IGF1R, INSR |
| BP | GO:0009987; cellular process | GO:0051259; protein oligomerization | 2.079E-05 | 1.297E-03 | AR, BLM, BRAF, HBB, HSD17B10, IGF1R, INSR, SLC22A6, TEK, TP53 |
| BP | GO:0008283; cell proliferation | GO:0001938; positive regulation of endothelial cell proliferation | 2.101E-05 | 1.300E-03 | AKT1, FLT4, HIF1A, KDR, TEK |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 2.162E-05 | 1.330E-03 | AKT1, CYP1B1, DAPK1, GSK3B, HPGD, NOX4, PDGFRB, SMAD3, SRC, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.036E-05 | 1.797E-03 | ALOX15, ALOX5, HPGD |
| CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 3.496E-05 | 2.036E-03 | ABCG2, AHR, EGFR, ERBB2, FLT4, IGF1R, INSR, SMAD3 |
| BP | GO:0009987; cellular process | GO:0070507; regulation of microtubule cytoskeleton organization | 3.566E-05 | 2.071E-03 | AURKA, GSK3B, HSPA1A, MET, PLK1, PLK4 |
| BP | GO:0050896; response to stimulus | GO:0051591; response to cAMP | 3.579E-05 | 2.073E-03 | APEX1, BRAF, NOX4, TEK, TYR |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 3.819E-05 | 2.200E-03 | AKR1B1, APEX1, AURKA, CA4, EGFR, ERBB2, HSPA1A, NOX4, SRC, TYR, USP2 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 4.141E-05 | 2.373E-03 | AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKA, AURKB, BLM, CSNK2A1, CTDSP1, DUSP3, ESRRA, GSK3B, HIF1A, HPGD, HSPA1A, LMNA, NUAK1, PLK1, POLB, RECQL, SMAD3, SRC, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.452E-05 | 2.518E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.452E-05 | 2.518E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 5.256E-05 | 2.912E-03 | AKT1, HIF1A, LMNA, SRC, TP53 |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 5.315E-05 | 2.937E-03 | AURKA, AURKB, PLK1, POLB |
| BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 7.938E-05 | 4.257E-03 | AKR1B1, APEX1, BLM, GAA, HIF1A, NOX4, SRC |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 8.211E-05 | 4.340E-03 | HIF1A, SMAD3, TP53 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.881E-05 | 4.604E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 8.842E-05 | 4.604E-03 | AHR, AR, GSK3B, SMAD3, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 9.028E-05 | 4.670E-03 | AKT1, AR, BRAF, CA2, CTDSP1, CYP1B1, EGFR, ERBB2, ESRRA, GSK3B, HIF1A, INSR, KDR, PDGFRB, PTK2, SMAD3, SRC, TEK, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.416E-05 | 4.813E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005215; transporter activity | GO:0015347; sodium-independent organic anion transmembrane transporter activity | 1.073E-04 | 5.384E-03 | SLC22A6, SLCO1B1, SLCO1B3 |
| BP | GO:0008152; metabolic process | GO:2000573; positive regulation of DNA biosynthetic process | 1.117E-04 | 5.576E-03 | AURKB, NOX4, PDGFRB, SRC |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 1.212E-04 | 6.024E-03 | CYP1A2, EGFR, ESRRA, HPGD, PDGFRB |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 1.259E-04 | 6.231E-03 | EGFR, ERBB2, MET, PDGFRB |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.279E-04 | 6.318E-03 | AHR, AURKA, BRAF, EGFR, ERBB2, HIF1A, SMAD3, TP53, TYR |
| MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 1.335E-04 | 6.563E-03 | APEX1, BLM, POLB, TP53 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.401E-04 | 6.765E-03 | AHR, AKR1B1, AKT1, ALOX15, ALOX5, AR, AURKA, AURKB, BLM, BRAF, CA13, CA2, CA7, CSNK2A1, DUSP3, EPHB4, ERBB2, FLT3, GSK3B, HBB, HIF1A, HPGD, HSD17B1, HSPA1A, LMNA, MAP3K8, PLK1, PLK4, PTK2, SMAD3, SRC, TP53, TYR, XDH |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.414E-04 | 6.784E-03 | BACE1, EGFR, INSR, KDR, SLC22A6, SRC, TEK |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.476E-04 | 6.943E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 1.476E-04 | 6.943E-03 | BLM, RECQL |
| CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 1.476E-04 | 6.943E-03 | AURKA, AURKB |
| BP | GO:0065007; biological regulation | GO:0043281; regulation of cysteine-type endopeptidase activity involved in apoptotic process | 1.494E-04 | 7.009E-03 | AKT1, CSNK2A1, DAPK1, SMAD3, SRC, XDH |
| BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 1.513E-04 | 7.054E-03 | AKT1, EGFR, PLK1, SMAD3, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.538E-04 | 7.125E-03 | CYP1B1, FLT4, HIF1A |
| BP | GO:0008152; metabolic process | GO:0010605; negative regulation of macromolecule metabolic process | 1.569E-04 | 7.255E-03 | AHR, AKT1, APEX1, AR, AURKB, BLM, CSNK2A1, CTDSP1, DAPK1, DUSP3, EGFR, ESRRA, GSK3B, HIF1A, HSPA1A, IGF1R, KDR, PLK1, SMAD3, SRC, TP53, USP2, XDH |
| BP | GO:0051179; localization | GO:0043252; sodium-independent organic anion transport | 1.718E-04 | 7.857E-03 | SLC22A6, SLCO1B1, SLCO1B3 |
| BP | GO:0065007; biological regulation | GO:0051336; regulation of hydrolase activity | 1.743E-04 | 7.959E-03 | AKT1, CSNK2A1, DAPK1, EGFR, ERBB2, GSK3B, HSPA1A, NUAK1, PDGFRB, PTK2, SMAD3, SRC, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.766E-04 | 8.045E-03 | FLT4, KDR, PTK2, SRC |
| BP | GO:0048511; rhythmic process | GO:0007623; circadian rhythm | 1.868E-04 | 8.476E-03 | AHR, EGFR, GSK3B, TP53, USP2 |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.910E-04 | 8.595E-03 | IGF1R, INSR, PDGFRB |
| BP | GO:0009987; cellular process | GO:0071383; cellular response to steroid hormone stimulus | 1.964E-04 | 8.744E-03 | AR, EGFR, FLT3, SRC |
| BP | GO:0009987; cellular process | GO:1901991; negative regulation of mitotic cell cycle phase transition | 1.981E-04 | 8.785E-03 | AURKA, AURKB, BLM, CTDSP1, PLK1, TP53 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.209E-04 | 9.620E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0035174; histone serine kinase activity | 2.209E-04 | 9.620E-03 | AURKA, AURKB |
| BP | GO:0022610; biological adhesion | GO:0022407; regulation of cell-cell adhesion | 2.244E-04 | 9.734E-03 | AKT1, ALOX15, BRAF, DUSP3, ERBB2, MAP3K8, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.337E-04 | 9.979E-03 | AKT1, CYP1A2, EGFR |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 2.337E-04 | 9.979E-03 | ABCC1, ALOX15, ALOX5 |
| CC | GO:0043226; organelle | GO:0051233; spindle midzone | 2.337E-04 | 9.979E-03 | AURKA, AURKB, PLK1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.993E-19 | 2.610E-15 | CA12, CA13, CA14, CA2, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.322E-16 | 1.845E-12 | CA12, CA13, CA14, CA2, CA4, CA5A, CA6, CA7, CA9, HBB |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 6.400E-15 | 8.710E-12 | ABCC1, ABCG2, AKT1, AURKA, AURKB, BLM, BRAF, CSNK2A1, DAPK1, EGFR, EPHB4, ERBB2, FLT3, FLT4, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MET, NUAK1, PDGFRB, PLK1, PLK4, PTK2, RECQL, SRC, TEK, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.117E-18 | 3.429E-16 | CA12; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.736E-11 | 9.374E-10 | PDGFRB; GSK3B; SMAD3; FLT3; DAPK1; BRAF; HIF1A; EGFR; PTK2; IGF1R; AR; ERBB2; AKT1; MET; TP53 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.215E-11 | 9.374E-10 | PDGFRB; GSK3B; SRC; FLT4; ERBB2; KDR; AKT1; BRAF; MET; PTK2; EGFR; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.467E-11 | 1.809E-09 | PDGFRB; GSK3B; AR; ERBB2; AKT1; BRAF; TP53; EGFR; IGF1R |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.494E-10 | 6.734E-09 | SRC; ERBB2; KDR; AKT1; BRAF; TP53; HIF1A; MET; PTK2; EGFR; IGF1R |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.455E-10 | 4.715E-09 | PDGFRB; FLT3; ERBB2; AKT1; TP53; MET; HIF1A; EGFR |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 3.767E-10 | 7.627E-09 | PDGFRB; SRC; INSR; FLT4; KDR; AKT1; BRAF; TEK; MET; EGFR; IGF1R |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.293E-10 | 7.622E-09 | SMAD3; CSNK2A1; SRC; INSR; ERBB2; MET; EGFR; IGF1R |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.965E-09 | 8.043E-08 | PDGFRB; GSK3B; INSR; FLT4; KDR; AKT1; TEK; TP53; MET; PTK2; EGFR; IGF1R |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 6.875E-10 | 1.237E-08 | HSD17B1; ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; IGF1R |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 8.598E-09 | 1.241E-07 | PDGFRB; AKT1; BRAF; TP53; MET; EGFR; IGF1R |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 3.590E-08 | 4.168E-07 | PLK4; SMAD3; INSR; PLK1; AKT1; BRAF; EGFR; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 3.602E-08 | 4.168E-07 | GSK3B; SRC; ERBB2; AKT1; BRAF; EGFR; PTK2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 9.190E-09 | 1.241E-07 | DAPK1; SRC; ERBB2; BRAF; TP53; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 4.028E-08 | 4.350E-07 | GSK3B; ERBB2; AKT1; BRAF; TP53; EGFR |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.749E-07 | 1.349E-06 | PDGFRB; INSR; FLT4; KDR; AKT1; TEK; MET; EGFR; IGF1R |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.572E-07 | 1.341E-06 | PDGFRB; AKT1; BRAF; TP53; EGFR; IGF1R |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.164E-07 | 1.048E-06 | INSR; ERBB2; AKT1; TEK; HIF1A; EGFR; IGF1R |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.725E-07 | 1.349E-06 | SMAD3; ERBB2; AKT1; BRAF; TP53; EGFR |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.866E-08 | 7.496E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 5.051E-06 | 3.273E-05 | PDGFRB; DUSP3; AKT1; BRAF; MAP3K8; TP53; EGFR; HSPA1A |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.131E-06 | 1.501E-05 | ERBB2; AKT1; BRAF; TP53; EGFR |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.339E-07 | 4.668E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.548E-06 | 2.395E-05 | GSK3B; SMAD3; AKT1; BRAF; TP53 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 5.280E-05 | 3.055E-04 | SMAD3; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.169E-08 | 7.259E-07 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.976E-06 | 4.786E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.954E-06 | 4.333E-05 | SLCO1B1; CA2; SLCO1B3; CYP3A4; ABCG2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.885E-05 | 3.287E-04 | HPGD; FLT3; TP53; MET; PTK2; IGF1R |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.359E-05 | 3.434E-04 | CYP2C9; ALOX5; ALOX15; BRAF; CYP2C19 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.151E-05 | 4.126E-04 | GSK3B; SRC; AKT1; TP53; HIF1A |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.242E-04 | 5.440E-04 | PDGFRB; ABCC1; ERBB2; CYP1B1; TP53; MET; EGFR |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.817E-04 | 6.847E-04 | GAA; ALOX15; AKR1B1; CYP2C19; CYP3A4; TYR; HSD17B10; CYP2C9; HSD17B1; ALOX5; HSD17B2; CYP1A2; CYP1A1; XDH |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 8.096E-05 | 4.126E-04 | SRC; KDR; AKT1; PTK2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.591E-04 | 6.287E-04 | GSK3B; CSNK2A1; AKT1; TP53; HSPA1A |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.433E-04 | 5.805E-04 | GSK3B; AKT1; BRAF; TP53; EGFR |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 9.773E-05 | 4.657E-04 | INSR; AKT1; HSPA1A; IGF1R |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 4.160E-04 | 1.532E-03 | PDGFRB; POLB; GSK3B; SMAD3; AKT1; TP53 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.629E-05 | 4.236E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.102E-04 | 4.961E-04 | AKT1; BRAF; MET; HIF1A |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 4.793E-04 | 1.652E-03 | PDGFRB; FLT3; FLT4; KDR; MET; EGFR |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.038E-04 | 4.807E-04 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.632E-04 | 6.295E-04 | SMAD3; AKT1; BRAF; TP53 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 4.309E-04 | 1.551E-03 | INSR; AKT1; TP53; IGF1R |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.311E-04 | 5.589E-04 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 9.735E-04 | 3.033E-03 | GSK3B; CSNK2A1; AKT1; TP53; HSPA1A |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 5.047E-04 | 1.703E-03 | PLK1; AKT1; BRAF; IGF1R |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 6.885E-04 | 2.187E-03 | GSK3B; SRC; AKT1; BRAF; PTK2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 5.245E-04 | 1.734E-03 | SRC; AKT1; EGFR; HSPA1A |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 5.657E-04 | 1.833E-03 | PDGFRB; AKT1; HIF1A; EGFR |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.258E-03 | 3.640E-03 | PDGFRB; SRC; BRAF; PTK2; EGFR |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.079E-03 | 3.297E-03 | GSK3B; AKT1; BRAF; TP53 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.182E-03 | 3.546E-03 | AR; PLK1; AURKA; IGF1R |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.218E-03 | 3.588E-03 | GSK3B; SMAD3; PLK1; TP53 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.331E-03 | 3.717E-03 | GSK3B; MET; PTK2; EPHB4 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.004E-03 | 5.236E-03 | GSK3B; SMAD3; AKT1; IGF1R |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.004E-03 | 5.236E-03 | GSK3B; SMAD3; CSNK2A1; TP53 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.854E-03 | 5.005E-03 | GSK3B; INSR; AKT1; BRAF |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.109E-03 | 5.394E-03 | PDGFRB; INSR; AKT1; EGFR |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.217E-03 | 5.525E-03 | SMAD3; SRC; AKT1; TP53 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 8.001E-03 | 1.728E-02 | GSK3B; INSR; AKT1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.571E-02 | 3.066E-02 | LMNA; AKT1; TP53 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 7.033E-03 | 1.540E-02 | GSK3B; AKT1; MAP3K8 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 9.932E-03 | 2.117E-02 | ALOX5; AKT1; HSPA1A |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.136E-02 | 2.359E-02 | INSR; AKT1; IGF1R |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.039E-02 | 2.187E-02 | ABCC1; AKT1; TP53 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.918E-02 | 3.612E-02 | GSK3B; INSR; AKT1 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 1.541E-02 | 3.045E-02 | CSNK2A1; SRC; AKT1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.530E-02 | 4.658E-02 | BACE1; GSK3B; HSD17B10 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 4.147E-03 | 9.737E-03 | AKT1; TP53; PTK2 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 4.423E-03 | 1.024E-02 | PDGFRB; SRC; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.509E-03 | 6.158E-03 | GSK3B; SRC; AKT1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.487E-03 | 4.082E-03 | AKT1; BRAF; HIF1A |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 3.149E-03 | 7.615E-03 | SRC; MET; PTK2 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.281E-03 | 3.642E-03 | FLT3; AKT1; BRAF |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.131E-03 | 5.394E-03 | SRC; MET; EGFR |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.529E-04 | 1.595E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 2.135E-02 | 3.975E-02 | BRAF; IGF1R |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.875E-02 | 3.574E-02 | INSR; AKT1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.813E-02 | 3.496E-02 | GSK3B; TP53 |
| hsa05144 | Malaria_Homo sapiens_hsa05144 | 1.456E-02 | 2.913E-02 | HBB; MET |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.291E-02 | 2.614E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.186E-02 | 2.431E-02 | ABCC1; ABCG2 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.276E-03 | 1.204E-02 | BRAF; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.639E-03 | 1.269E-02 | GAA; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 6.795E-03 | 1.508E-02 | POLB; APEX1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.336E-03 | 7.947E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.377E-04 | 5.722E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| NA: NA | HIV infections | NA | AHR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; TEK |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; KDR; KDR; KDR; EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; SRC; AURKB |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | FLT4; KDR; MET; IGF1R |
| C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | BRAF; TP53; PTK2; AURKA |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
| C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; HIF1A; INSR; CA9; ERBB2; EGFR; PLK1 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; IGF1R |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | BRAF; TYR; KDR; KDR; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | BRAF; KDR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT4; AR; AR; FLT3; ERBB2; EGFR; PLK1 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT4; KDR; KDR; KDR; AKT1; HIF1A; TP53; MET; SRC; FLT3; CA9; ERBB2; EGFR; PDGFRB; TEK; PLK1; PLK1; PTK2; IGF1R; AURKB; AURKA |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; TP53; FLT3; ERBB2; EGFR; EGFR; IGF1R |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; SRC; IGF1R |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; TEK; ABCC1; ESRRA |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; KDR; TP53; EGFR; EGFR; EGFR; AKR1B1 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | FLT4; EGFR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3; PLK1; AURKB; AURKA |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PLK1; AURKA |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
| C00-D49: Neoplasms | Solid tumors | NA | BRAF |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; GSK3B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| C00-D49: Neoplasms | Cancer | C00-C96 | BRAF; BRAF; FLT4; EPHB4; AR; KDR; AKT1; HIF1A; TP53; MET; SRC; FLT3; FLT3; CA9; CSNK2A1; ERBB2; ERBB2; EGFR; TEK; PLK1; GSK3B; PTK2; IGF1R; AURKA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; KDR; KDR; KDR; INSR; FLT3; FLT3; CA9; ERBB2; ERBB2; ERBB2; EGFR; EGFR; EGFR; IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; PDGFRB; GSK3B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; ERBB2; EGFR |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | KDR; MET; EGFR; EGFR; PDGFRB; IGF1R; IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; ESRRA |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | ERBB2; PLK1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; ERBB2; ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; EGFR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; ERBB2; EGFR; EGFR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; ERBB2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; AKR1B1; ESRRA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR; ERBB2; EGFR; EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; INSR; IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | BRAF |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; AKT1; FLT3; EGFR; PLK1 |